On the recordSeptember 16, 2015
Has FDA analyzed, No. 1, the extent to which these cost of changing names is passed on to healthcare payers and consumers?
Source
congress.govEditor's note · Context
Senator Hatch questions FDA about cost impacts on healthcare from name changes.
Share & report
More from Orrin Hatch
Jun 25, 2018
When the President said in early 2017 that drug companies were 'getting away with murder,' he offered his diagnosis of the prescription drug cost problem.
Jun 25, 2018
I believe that those who have criticized the blueprint as insufficient are either responding from a lack of knowledge or purely for political gain.
Other voices in this conversation
